It appears we're poised to enter a new liquidity zone once we surpass the $2.60 mark. I plan to buy shares at the lower boundary of $1.89, and will keep adding to my position if prices drop further. Despite the less-than-ideal financials at present, the future looks promising once the company activates its data centers and commercializes its GPUs. The potential...
I realize these guys financials are trash, But I really like the business model, This is a long term hold for me as I believe Data is the next gold rush. Not worried about the lawsuits, those guys throw them around left and right, the accusations don't seem too worrisome. My key buy areas are the LVNs, $2.90-$3.00 Area, here.... Depending on earnings ill make...
TOMI Environmental Solutions, Inc. specializing in proprietary hydrogen peroxide-based SteraMist technology for disinfection and decontamination, appears undervalued despite a post-COVID-19 demand slump. With shares down over 94% from their peak, the market overlooks TOMI's resurgence potential, underscored by expected 25% annual EPS growth from $0.06 in 2024 to...
APLD operates in the high-demand sectors of AI cloud services and next-generation data centers, benefiting from key trends in artificial intelligence and digital infrastructure. The company's strategy involves renting out data center space crucial for AI development, rather than creating AI algorithms itself. This approach has led to significant revenue growth,...
Hit my buy target over the weekend, see previous post. We are sitting ok at this level. Bulls are putting up a little fight, sellers seem to be not as aggressive here. "IF" we break below this area, my next buy target is .000024, If we hit that I will re evaluate. Remember, we are likely heading into a bull cycle, and its just begun, this gives more time for...
We have entered into the upper trading range with good volume, Now targeting .00003192 as my accumulation are, if we don't hit it so be it, but this is the true support, see LVN, LVS are areas where you see the lack of aggressive buyers or sellers depending on which side of the PoC it is, Top or Bottom. It will be interesting to see, .0000.3731 is a really...
Still seeing volume effects of eating seller liquidity. Looking good.
We're venturing into the territory of previous highs in terms of liquidity. It's an exciting time! Our short-term goal is the .00012 area, which could yield almost a 400% return based on short-term forecasts using Fibonacci extensions and retracements. Remember to secure your gains! Don't hold on hoping against hope, similar to what happened with AMC...
Speculative play, not a huge amount invested.. BUT.. "ACHR stock, paying up today for a (possible) big payoff tomorrow may just well be worth it. The commercialization stage is just around the corner. As Archer discussed in its latest investor presentation, the company is now in the final phase of obtaining certification from the Federal Aviation Administration...
The volume surges observed significantly impact the asset's behavior, with each spike occurring at key support levels, often resulting in a bullish reversal hammer candlestick pattern on larger timeframes or contributing to upward momentum. Conversely, periods of bearish trends are characterized by lower volume, suggesting an accumulation phase. Breaking above the...
Refer to my earlier post on SHIB for my buy levels, which 2/3 hit right on. Currently, we're observing the formation of an inverse head and shoulders pattern. To confirm a bullish trend, we need to surpass the Low Volume Node (LVN) with significant trading volume, which would indicate potential for upward movement. Crossing my yellow line with volume will send us...
AGEN, a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Leerink Global Biopharma Conference on March 11th - 13th in Miami Beach, Florida. The fireside chat will take place at 2:30 p.m. ET on...
The recent advancements by Acurx Pharmaceuticals, Inc. in the development of ibezapolstat, including the scheduling of an End of Phase 2 (EOP2) meeting with the FDA for late April 2024 and the acquisition of SME designation from the European Medicines Agency (EMA), are bullish indicators for the company and its stakeholders. These milestones are significant as...
Refer to my earlier post on SHIB for my buy levels, which 2/3 hit right on. Currently, we're observing the formation of an inverse head and shoulders pattern. To confirm a bullish trend, we need to surpass the Low Volume Node (LVN) with significant trading volume, which would indicate potential for upward movement. Crossing my yellow line with volume will send us...
PowerFleet (NASDAQ:PWFL) stands out as a key innovator within the Internet-of-Things (IoT) and fleet management sectors, providing solutions to secure, track, and manage high-value assets like industrial vehicles and shipping containers. Positioned in a rapidly growing market projected to expand significantly by 2030, PowerFleet's current modest market cap of...
I notice plenty of pessimistic predictions alongside optimistic analyses claiming a bullish trend, including assertions that "INDICATORS SHOW BULLISH" - which I find unreliable. Oscillating indicators are not effective unless applied to mean-reverting stocks, and cryptocurrencies do not fit this category nor does the current market environment. Additionally, the...
Small position in calls here, per last call transcript, fuboTV Inc. exceeded Q4 2023 earnings expectations with an EPS of -$0.17 against a forecast of -$0.25. The report highlighted significant year-over-year growth, including a 12% increase in paid subscribers and a 29% rise in total revenue. The company also reported a record $114 million in annual ad revenue, a...
Seastar Medical, operating within the rapidly growing biotechnology sector projected to reach $3879.51 billion by 2030, is at the forefront with its Selective Cytopheretic Device (SCD) aimed at treating excessive inflammation through extracorporeal therapies. Despite a significant financial downturn, with a 400% decrease in income and a substantial increase in...